Business
Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters
Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. The data—presented publicly for the first time —demonstrates strong performance compared to other super-bore catheters in key performance metrics such as trackability, atraumatic design and overall physici
About this update from Terumo Corporation
[{"type":"text","content":"Real-World U.S. Physician Preference Data1 Demonstrates the SOFIA™ 88 Catheter's Trackability, Atraumatic Design, and Overall Performance in Stroke Procedures","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn., July 14, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. The data—presented publicly for the first time —demonstrates strong performance compared to other super-bore catheters in key performance metrics such as trackability, atraumatic design and overall physician-rated experience.","length":568,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":94,"height":480,"url":"https://media.zenfs.com/en/prnewswire.com/a2e2a7c16bd8326b22ab1e3db7105d80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXWRZfFJP6CZlWX8noW2kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTU2MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a2e2a7c16bd8326b22ab1e3db7105d80","width":94,"height":480}},"href":"https://mma.prnewswire.com/media/2730032/2025_07_SNIS_PressRelease_PPT.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Collected from 105 procedures across 37 U.S. centers and 41 physicians, the preference test revealed:","length":101,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"95% of physicians reported that SOFIA™ 88 catheter reliably reached the target location—even in anatomically challenging cases, with 59% of procedures in ICA-T or beyond","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"86% of physicians rated the SOFIA™ 88 catheter as "Better" or "Much Better" than alternatives overall","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Physician data included: SOFIA™ 88 catheter outperformed the ZOOM 88 catheter in 94% of cases and the HiPoint 88 catheter in 79%","length":128,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":418,"olType":false},{"type":"text","content":""These real-world results further validate SOFIA™ 88 ca...